<DOC>
	<DOCNO>NCT01770834</DOCNO>
	<brief_summary>This prospective , observational study evaluate efficacy , safety tolerability RoActemra/Actemra ( tocilizumab ) patient moderate severe active rheumatoid arthritis inadequate response intolerant one conventional disease-modifying anti-rheumatic drug . Data collect patient initiated RoActemra/Actemra treatment accord local label baseline , Weeks 4 , 12 24 , 3 6 month last dose study drug .</brief_summary>
	<brief_title>A Prospective , Non-Interventional Study RoActemra/Actemra ( Tocilizumab ) Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 21 year age Moderate severe active rheumatoid arthritis ( DAS28 &gt; /= 3.2 ) Inadequate response one conventional diseasemodifying antirheumatic drug ( DMARDs ) Initiated RoActemra/Actemra treatment accordance prescribe information Pregnant lactating woman Contraindication RoActemra/Actemra treatment accord local label Previous treatment tocilizumab Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra Women childbearing potential use effective method contraception define protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>